Regulatory Scrutiny Intensifies for Hims & Hers Following Super Bowl Ad

FDA Launches Unusually Sharp Rebuke

The telehealth provider Hims & Hers finds itself navigating turbulent regulatory waters. Its recent expansion into the multi-billion dollar testosterone therapy market has been immediately overshadowed by a significant confrontation with the U.S. Food and Drug Administration (FDA). The clash was triggered by a multi-million dollar Super Bowl advertisement for weight-loss medications that the agency has flagged for an “egregious” violation of marketing rules, raising questions about potential constraints on the company’s aggressive growth strategy.